Neuroscientific Biopharmaceuticals (ASX:NSB) | Tech & Biotech Investor Webinar | September 2021
NeuroScientific Biopharmaceuticals (ASX: NSB) – Webinar Presentation
NeuroScientific Biopharmaceuticals taking a different approach to treat Alzheimer's Disease
Interview with NeuroScientific Biopharmaceuticals CEO and MD Matt Liddelow
Neuroscientific Biopharmaceuticals (ASX:NSB) - Broker Briefing Investor Webinar - March 2022
NeuroScientific Biopharmaceuticals targets neurodegenerative disorders with novel peptide solution
Neuroscientific Biopharmaceuticals (ASX:NSB) - Broker Briefing Investor Webinar - November 2021
NeuroScientific Biopharmaceuticals Investor Update Webinar 20th September 2022
NeuroScientific Biopharmaceuticals Investor Briefing Webinar 31 October 2023
NeuroScientific Biopharmaceuticals Ltd Investor Update 3 February 2023
Alexandra Heaton Interview - NeuroScientific Biopharmaceuticals
Presentation: Neuroscientific Biopharmaceuticals – 121 Tech Investment Hong Kong 2019 Spring
Presentation: NeuroScientific Biopharmaceuticals - 121 Tech Investment Singapore
Interview: Matt Liddelow, NeuroScientific Biopharmaceuticals - 121 Tech Investment Singapore 2018
TechKnow Roadshow Q&A: Brian Leedman
Peptide based therapies for neurodegenerative conditions
Neurotech International Limited (ASX: NTI) Day 2 of the IRD Invest 2021 conference.
#NeuroscientificBiopharmaceuticals announces #interimCEO #shortvideo #paulrennie #kalkinemedia
Drug Discovery in Neuroscience: Kevin Gorman (Ph.D. ’87, ’91), CEO, Neurocrine Biosciences
Putting the Bio in Biotech: The Challenges and Future of Biopharmaceuticals*
